# CDK4/6 Inhibitors in Metastatic HR-Positive Breast Cancer

> **NCT07704801** · — · ACTIVE_NOT_RECRUITING · sponsor: **Sohag University** · enrollment: 300 (estimated)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** CDK4/6 inhibitors

## Key facts

- **NCT ID:** NCT07704801
- **Lead sponsor:** Sohag University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-01-01
- **Primary completion:** 2026-11-01
- **Final completion:** 2027-04-01
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07704801

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07704801, "CDK4/6 Inhibitors in Metastatic HR-Positive Breast Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07704801. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*